Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: Current evidence

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 2181-2191

  Zalpour, Ali ^a   Oo, Thein Hlaing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apixaban; New oral anticoagulants; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANDEXANET ALFA; ANTIDOTE; APIXABAN; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; CONIVAPTAN; DABRAFENIB; ENOXAPARIN; FIBRINOGEN CONCENTRATE; FONDAPARINUX; HEPARIN; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENYTOIN; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; RITONAVIR; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE DISEASE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CANCER PATIENT; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEMOSTASIS; HIP SURGERY; HUMAN; KNEE SURGERY; ORTHOPEDIC SURGERY; PATIENT EDUCATION; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; VENOUS THROMBOEMBOLISM; ANIMAL;

ANIMALS; HUMANS; PYRAZOLES; PYRIDONES; VENOUS THROMBOEMBOLISM;

EID: 84908690045     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S51006     Document Type: Review

References (62)

1. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014;124(7):1020-1028.
2. Tun NM, Oo TH. Prevention and treatment of venous thromboembo-lism with new oral anticoagulants: a practical update for clinicians. Thrombosis. 2013;2013:183616.
3. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693.
4. Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012;13(73):445-450.
5. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3(8): 1843-1853.
6. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69-82.
7. Samama MM, Bara L, Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. Drugs. 1996;52 Suppl 7:8-14; discussion 14-15.
8. Turpie AG. New oral anticoagulants in atrial fbrillation. Eur Heart J. 2008;29(2):155-165.
9. Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012;72(9):1271-1291.
10. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specifc patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10.
11. Mahan C., Fanikos J. New antithrombotics: the impact on global health care. Thromb Res. 2011;127(6):518-524.
12. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxa-ban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010; 70(5):703-712.
13. ® (apixaban) tablets for oral use [prescribing information]. Princeton, NJ: Bristol-Myers Squbb Company; 2014. Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed July 1, 2014.
14. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.
15. O’Reilly RF, Burgess IA, Zicat B. The prevalence of venous throm-boembolism after hip and knee replacement surgery. Med J Aust. 2005;182(4):154-159.
16. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S.
17. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for throm-boprophylaxis after hip replacement. N Engl J Med. 2010;363(26): 2487-2498.
18. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.
19. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for throm-boprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.
20. Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost. 2011;105(2):245-253.
21. Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med. 2009;122(12): 1077-1084.
22. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. Stroke. 2001;32(1):262-267.
23. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-2177.
24. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005;12 Suppl 1:5-10.
25. Khorana AA, Dalal M, Tangirala K, Miao R. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients [Abstract]. Blood. 2013;118: Abstract 674.
26. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2012;2:CD008500.
27. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807-814.
28. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009;27 Suppl 1: 63-74.
29. Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204.
30. Streiff MB, Bockenstedt PL, Cataland SR, et al; National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013;11(11):1402-1429.
31. Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-e494S.
32. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
33. Agnelli G, Buller HR, Cohen A, et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
34. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2): 476-487.
35. Douxfls J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specifc coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110(2):283-294.
36. Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111(2):240-248.
37. Wood P. New oral anticoagulants: an emergency department overview. Emerg Med Australas. 2013;25(6):503-514.
38. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69(17):1473-1484.
39. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fbril-lation: executive summary. Eur Heart J. 2013;34(27):2094-2106.
40. Douketis JD, Spyropoulos AC, Spencer FA, et al; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-e350S.
41. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15): 2954-2962.
42. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164(12):1319-1326.
43. Spyropoulos AC, Turpie AG, Dunn AS, et al; REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost. 2006;4(6): 1246-1252.
44. Nutescu EA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70(10 Suppl 1):S3-S11.
45. Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fbrilla-tion unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fbrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012;43(12):3291-3297.
46. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fbrillation: what have we learned? Curr Cardiol Rep. 2014; 16(5):480.
47. Rashidi A, Tahhan HR. Fresh frozen plasma dosing for warfarin reversal: a practical formula. Mayo Clin Proc. 2013;88(3):244-250.
48. Meehan R, Tavares M, Sweeney J. Clinical experience with oral versus intravenous vitamin K for warfarin reversal. Transfusion. 2013; 53(3):491-498; quiz 490.
49. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: signifcance of studies in vitro with circulating human blood. PLoS One. 2013;8(11):e78696.
50. Martin AC, Le Bonniec B, Fischer AM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fbrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168(4):4228-4233.
51. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of pro-thrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011; 106(3):429-438.
52. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19): 1791-1800.
53. Ward C, Conner G, Donnan G, Gallus A, McRae S. Practical management of patients on apixaban: a consensus guide. Thromb J. 2013; 11(1):27.
54. Akwaa F, Spyropoulos AC. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr Treat Options Cardiovasc Med. 2013;15(3):288-298.
55. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specifc antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.
56. Keating GM. Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fbrillation. Drugs. 2013;73(8):825-843.
57. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011;31(12):1175-1191.
58. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5(3):433-451.
59. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Throm-bolysis. 2011;31(3):326-343.
60. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64(7):956-967.
61. APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-2885.
62. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.